%0 Journal Article
%A Acker, Fabian
%A Reck, Martin
%A Martin, Daniel
%A Rieken, Stefan
%A Heinzen, Sophie
%A Rost, Maximilian
%A Aguinarte, Lukas
%A Schulte, Hanna
%A Serve, Hubert
%A Oellerich, Thomas
%A Sebastian, Martin
%A Althoff, Friederike C
%T Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis.
%J European journal of cancer
%V 218
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-00279
%P 115266
%D 2025
%X In patients with unresectable, stage III non-small cell lung cancer (NSCLC), durvalumab maintenance after concurrent chemoradiotherapy (cCRT) was shown to improve survival over placebo. As subgroup analyses indicated better outcomes with earlier start of durvalumab, several trials evaluated concomitant checkpoint inhibition (CPI) with cCRT. However, this may introduce an increased risk of treatment-related pulmonary toxicity.We conducted a systematic review and meta-analysis of clinical trials of combined cCRT plus CPI followed by CPI maintenance in patients with stage III NSCLC. Endpoints included incidence of pneumonitis by any cause, objective response rate (ORR), progression-free (PFS), and overall survival (OS).A total of 7 trials comprising 653 patients were included. In trials of single-agent CPI with cCRT, pneumonitis occurred in 33 
%K Checkpoint inhibitor (Other)
%K Chemoradiotherapy (Other)
%K Locally advanced (Other)
%K Meta-analysis (Other)
%K NSCLC (Other)
%K Stage III (Other)
%K Systematic review (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39893747
%R 10.1016/j.ejca.2025.115266
%U https://inrepo02.dkfz.de/record/298423